Mortalité des adultes infectés par le VIH comparée à la population générale - Données à long terme et selon les lymphocytes CD4

1. Romo R, Hernandez A, Zainos A, et al. Sensing without touching : psychophysical performance based on cortical microstimulation. Neuron 2000 ; 26 : 273-8. 2. Romo R, Hernandez A, Zainos A, Salinas E. Somatosensory discrimination based on cortical microstimulation. Nature 1998 ; 392 : 387-90. 3. Butovas S, Schwarz C. Detection psychophysics of intracortical microstimulation in rat primary somatosensory cortex. Eur J Neurosci 2007 ; 25 : 2161-9. 4. Leal-Campanario R, Gado-Garcia JM, Gruart A. Microstimulation of the somatosensory cortex can substitute for vibrissa stimulation during Pavlovian conditioning. Proc Natl Acad Sci USA 2006 ; 103 : 10052-7. 5. Huber D, Petreanu L, Ghitani N, et al. Sparse optical microstimulation in barrel cortex drives learned behaviour in freely moving mice. Nature 2008 ; 451 : 61-4. 6. Houweling AR, Brecht M. Behavioural report of single neuron stimulation in somatosensory cortex. Nature 2008 ; 451 : 65-8. 7. Hatanaka Y, Hisanaga S, Heizmann CW, Murakami F. Distinct migratory behavior of earlyand late-born neurons derived from the cortical ventricular zone. J Comp Neurol 2004 ; 479 : 1-14. 8. Nagel G, Szellas T, Huhn W, et al. Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. Proc Natl Acad Sci USA 2003 ; 100 : 13940-5. 9. Boyden ES, Zhang F, Bamberg E, et al. Millisecondtimescale, genetically targeted optical control of neural activity. Nat Neurosci 2005 ; 8 : 1263-8. 10. Tehovnik EJ. Electrical stimulation of neural tissue to evoke behavioral responses. J Neurosci Methods 1996 ; 65 : 1-17. 11. Knopfel T. Expanding the toolbox for remote control of neuronal circuits. Nat Methods 2008 ; 5 : 293-5.

[1]  C. Katlama,et al.  HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population , 2007, Journal of acquired immune deficiency syndromes.

[2]  B. Gazzard,et al.  When should antiretroviral therapy for HIV be started? , 2007, BMJ : British Medical Journal.

[3]  Kholoud Porter,et al.  Determinants of survival following HIV-1 seroconversion after the introduction of HAART , 2003, The Lancet.

[4]  B. Spire,et al.  Les enjeux économiques et sociaux de l’infection par le VIH à l’ère des multithérapies antirétrovirales : Apports des sciences humaines et sociales , 2003 .

[5]  C. Sabin,et al.  Antiretroviral drugs and the risk of myocardial infarction - Reply , 2007 .

[6]  C. Fraser,et al.  CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater , 2007, Journal of acquired immune deficiency syndromes.

[7]  J. Sterne,et al.  Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies , 2003, The Lancet.

[8]  C. Vigouroux,et al.  Les lipodystrophies secondaires aux traitements antirétroviraux de l’infection par le VIH , 2006 .

[9]  O. Kirk,et al.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. , 2006, Archives of internal medicine.

[10]  W. Howard.  Class of Antiretroviral Drugs and the Risk of Myocardial Infarction , 2008 .

[11]  A. Ghani,et al.  Mortality in Patients With Successful Initial Response to Highly Active Antiretroviral Therapy Is Still Higher Than in Non-HIV-Infected Individuals , 2005, Journal of acquired immune deficiency syndromes.